Gershon Y. Locker

12.6k total citations · 6 hit papers
76 papers, 9.5k citations indexed

About

Gershon Y. Locker is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gershon Y. Locker has authored 76 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 28 papers in Cancer Research and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gershon Y. Locker's work include PARP inhibition in cancer therapy (24 papers), Pancreatic and Hepatic Oncology Research (23 papers) and Cancer Genomics and Diagnostics (16 papers). Gershon Y. Locker is often cited by papers focused on PARP inhibition in cancer therapy (24 papers), Pancreatic and Hepatic Oncology Research (23 papers) and Cancer Genomics and Diagnostics (16 papers). Gershon Y. Locker collaborates with scholars based in United States, United Kingdom and South Korea. Gershon Y. Locker's co-authors include James H. Doroshow, Charles E. Myers, Jack Cuzick, Anthony Howell, Robert C. Bast, J. Milburn Jessup, Nancy E. Kemeny, Mark R. Somerfield, Daniel F. Hayes and G Hoctin-Boes and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Gershon Y. Locker

75 papers receiving 9.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer

2005 1.7k citations Anthony Howell, Jack Cuzick et al. profile →
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

2019 1.5k citations Talia Golan, Pascal Hammel et al. New England Journal of Medicine profile →
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer

2006 1.2k citations Gershon Y. Locker, J. Milburn Jessup et al. Journal of Clinical Oncology profile →
2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*

2001 660 citations Robert C. Bast, Peter M. Ravdin et al. Journal of Clinical Oncology profile →
Enzymatic Defenses of the Mouse Heart Against Reactive Oxygen Metabolites

1980 583 citations Gershon Y. Locker et al. profile →
Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers

1996 553 citations D. F. Hayes, Robert C. Bast et al. JNCI Journal of the National Cancer Institute profile →

Peers

Countries citing papers authored by Gershon Y. Locker

Since Specialization

Citations

This map shows the geographic impact of Gershon Y. Locker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gershon Y. Locker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gershon Y. Locker more than expected).

Fields of papers citing papers by Gershon Y. Locker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gershon Y. Locker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gershon Y. Locker. The network helps show where Gershon Y. Locker may publish in the future.

Co-authorship network of co-authors of Gershon Y. Locker

This figure shows the co-authorship network connecting the top 25 collaborators of Gershon Y. Locker. A scholar is included among the top collaborators of Gershon Y. Locker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gershon Y. Locker. Gershon Y. Locker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient‐centered outcomes in the POLO study of active maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer 2023 ·Cancer ·Hedy L. Kindler, (unknown), Robert Hettle, Karen Cui, (unknown), Gershon Y. Locker, Talia Golan	8
2	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer 2022 ·Journal of Clinical Oncology ·Hedy L. Kindler, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, Sonal Bordia, David McGuinness, Karen Cui, Gershon Y. Locker, Talia Golan	120
3	Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer breakdown → 2019 ·New England Journal of Medicine ·Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, (unknown), Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, David McGuinness, Karen Cui, Katia Schlienger, Gershon Y. Locker, Hedy L. Kindler	1468
4	gastrointestinal tumours, non-colorectal Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy: Phase III GOLD study 2016 ·Annals of Oncology ·Y-J. Bang, Narikazu Boku, (unknown), Kyung-Woo Lee, S.H. Park, Shukui Qin, Sun Young Rha, Lin Shen, Nong Xu, S.-A. Im, Gershon Y. Locker, Philip Rowe, (unknown), Darren Hodgson, YZ Liu, Rui‐Hua Xu	9
5	POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2mutation (gBRCAm) who have not progressed following first-line chemotherapy. 2015 ·Journal of Clinical Oncology ·Hedy L. Kindler, Gershon Y. Locker, Helen Mann, Talia Golan	9
6	Second-line therapy of KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) with the MEK inihibitor selumetinib ([SEL], AZ6244, ARRY-142886) in combination with irinotecan (IRI): An AGICC study. 2013 ·Journal of Clinical Oncology ·Howard S. Höchster, Wells A. Messersmith, Bert H. O’Neil, Susan Groshen, Deirdre Jill Cohen, Crystal S. Denlinger, Philip J. Gold, Sabine Eckhardt, Gershon Y. Locker, (unknown), Marti McKinley, Lawrence P. Leichman	7
7	The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC). 2013 ·Journal of Clinical Oncology ·Howard S. Höchster, Wells A. Messersmith, Bert H. O’Neil, Susan Groshen, Heinz‐Josef Lenz, Deirdre Jill Cohen, Crystal S. Denlinger, Philip J. Gold, Sabine Eckhardt, Gershon Y. Locker, (unknown), Marti McKinley, Lawrence P. Leichman	4
8	Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium 2010 ·Investigational New Drugs ·Hedy L. Kindler, Kristen Wroblewski, James A. Wallace, Michael J. Hall, Gershon Y. Locker, Sreenivasa Nattam, Edem Agamah, Walter M. Stadler, Everett E. Vokes	87
9	Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial 2007 ·British Journal of Cancer ·(unknown), Robert E. Mansel, Gershon Y. Locker, Lesley Fallowfield, Ágnes Benedict, David A. Jones	47
10	Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial 2007 ·Breast Cancer Research and Treatment ·Gershon Y. Locker, Robert E. Mansel, David Cella, Deborah Dobrez, Sonja Sorensen, Sanjay Gandhi, (unknown)	62
11	Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer 2006 ·Breast Cancer Research and Treatment ·David Cella, Lesley Fallowfield, Peter Barker, Jack Cuzick, Gershon Y. Locker, Anthony Howell, (unknown)	201
12	The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features 2006 ·Cancer Genetics and Cytogenetics ·Gershon Y. Locker, Karen L. Kaul, David S. Weinberg, Zoran Gatalica, Gordon Gong, Amy H. Peterman, Jane F. Lynch, (unknown), Olufunmilayo I. Olopade, (unknown), Anna Newlin, Eileen Keenan, (unknown), Joseph A. Knezetic, (unknown), Henry T. Lynch	12
13	Regulation of Fatty Acid Synthase (FAS) gene expression by Peroxisome Proliferator-activated receptor-gamma (PPARγ) is dependent of Her-2/neu (erbB-2) signaling in breast cancer cells 2005 ·Cancer Research ·Javier A. Menéndez, Gershon Y. Locker, Ruth Lupu	3
14	Defining the Roles of Aromatase Inhibitors in the Adjuvant Treatment of Early-Stage Breast Cancer 2005 ·Clinical Breast Cancer ·Anthony Howell, Gershon Y. Locker	6
15	Breast surgery in the ‘Arimidex, Tamoxifen Alone or in Combination’ (ATAC) trial 2004 ·Cancer ·Gershon Y. Locker, J R C Sainsbury, Jack Cuzick	27
16	Cancer in Jews: introduction and overview 2004 ·Familial Cancer ·Henry T. Lynch, Wendy S. Rubinstein, Gershon Y. Locker	22
17	Breast surgery in the ATAC trial: women from the United States are more likely to have mastectomy. 2002 ·UCL Discovery (University College London) ·Gershon Y. Locker, R Sainsbury, J. Cuzick, (unknown)	6
18	Hormonal therapy of breast cancer 1998 ·Cancer Treatment Reviews ·Gershon Y. Locker	42
19	Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers breakdown → 1996 ·JNCI Journal of the National Cancer Institute ·D. F. Hayes, Robert C. Bast, Christopher E. Desch, Herbert A. Fritsche, Nancy E. Kemeny, J. Milburn Jessup, Gershon Y. Locker, J. S. Macdonald, Robert Mennel, Larry Norton, Peter M. Ravdin, Sheila E. Taube, R Winn	553
20	High-dose aminothiadiazole in advanced colorectal cancer 1994 ·Investigational New Drugs ·Gershon Y. Locker, (unknown), Janardan D. Khandekar, Thomas E. Lad, Richard H. Knop, Kathy S. Albain, Richard R. Blough, (unknown), Al B. Benson	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact